SLNO Swings to Profit on VYKAT XR Launch, Cash Reserves Soar

TL;DR

**SLNO's VYKAT XR launch is a game-changer, turning massive losses into solid profits and making it a strong buy for growth-focused investors.**

AI Summary

Soleno Therapeutics Inc. (SLNO) reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $26.013 million, a stark contrast to the net loss of $76.616 million in the same period of 2024. This profitability was driven by the successful commercialization of VYKAT XR, its lead product candidate for Prader-Willi syndrome, which received FDA approval on March 26, 2025. The company recognized product revenue, net, of $66.018 million for the quarter and $98.675 million for the nine months ended September 30, 2025, compared to zero revenue in the prior year periods. Operating expenses decreased to $43.913 million for the quarter from $80.212 million year-over-year, primarily due to a substantial reduction in research and development expenses from $30.138 million to $8.405 million. Cash and cash equivalents surged to $246.662 million as of September 30, 2025, up from $87.928 million at December 31, 2024, bolstered by a July 2025 public offering that generated $215.721 million in net proceeds. The company's accumulated deficit decreased to $474.728 million from $500.741 million at June 30, 2025, reflecting the recent profitability.

Why It Matters

This filing signals a pivotal shift for Soleno Therapeutics, moving from a development-stage biotech with significant losses to a commercial-stage company generating substantial revenue and profit. For investors, the successful launch of VYKAT XR and the resulting $26.013 million net income demonstrate strong execution and market acceptance, potentially de-risking future investments. Employees benefit from the company's newfound financial stability and growth prospects. Customers, specifically patients with Prader-Willi syndrome, now have access to an FDA-approved treatment, VYKAT XR, which began deliveries in April 2025. In the competitive landscape, this successful commercialization establishes SLNO as a key player in the rare disease market, potentially attracting further partnerships or acquisition interest.

Risk Assessment

Risk Level: medium — While SLNO achieved profitability, the company still has an accumulated deficit of $474.7 million and relies on a single specialty pharmacy for distribution, creating a concentration risk. Furthermore, the company depends on sole-source suppliers and third-party manufacturers, which could materially impact future operating results if disrupted.

Analyst Insight

Investors should consider initiating or increasing positions in SLNO, given the successful commercial launch of VYKAT XR and the company's swing to profitability. Monitor future revenue growth and any diversification efforts in distribution or manufacturing to mitigate identified risks.

Financial Highlights

debt To Equity

0.20

revenue

$66.018M

operating Margin

33.5%

total Assets

$599.895M

total Debt

$49.854M

net Income

$26.013M

eps

N/A

gross Margin

N/A

cash Position

$246.662M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $26.013M — Net income for Q3 2025 (Significant turnaround from a $76.616M net loss in Q3 2024)
• $66.018M — Product revenue, net for Q3 2025 (First-time revenue recognition due to VYKAT XR launch)
• $246.662M — Cash and cash equivalents at Sep 30, 2025 (Increased from $87.928M at Dec 31, 2024, boosting liquidity)
• $215.721M — Net proceeds from July 2025 public offering (Major contributor to increased cash reserves)
• $474.728M — Accumulated deficit at Sep 30, 2025 (Reduced from $500.741M at June 30, 2025, indicating improving financial health)
• $8.405M — Research and development expenses for Q3 2025 (Decreased significantly from $30.138M in Q3 2024 post-approval)
• 53,710,025 — Shares outstanding as of Oct 31, 2025 (Reflects recent equity issuances)
• $50.0M — Debt outstanding under Oxford loan (Provides additional financing flexibility with potential for more tranches)

Key Players & Entities

• SOLENO THERAPEUTICS INC (company) — registrant
• VYKAT XR (company) — lead product candidate
• FDA (regulator) — approved VYKAT XR
• Prader-Willi syndrome (person) — disease treated by VYKAT XR
• Oxford Financing LLC (company) — loan provider
• Jefferies LLC (company) — sales agent for equity offerings
• Redwood City, California (location) — company headquarters
• Essentialis (company) — acquisition target with contingent liability

FAQ

Risk Factors

• Reliance on VYKAT XR Commercialization [high — financial]: The company's financial turnaround is heavily dependent on the successful and sustained commercialization of VYKAT XR. Any disruption in sales, market acceptance, or unexpected post-market issues could significantly impact revenue and profitability.
• Post-Market Regulatory Scrutiny [medium — regulatory]: While VYKAT XR received FDA approval, the company remains subject to ongoing regulatory oversight. Adverse events or manufacturing quality issues could lead to regulatory actions, product recalls, or restrictions, impacting sales and reputation.
• Manufacturing and Supply Chain [medium — operational]: Scaling up manufacturing and ensuring a robust supply chain for VYKAT XR is critical. Any disruptions or quality control failures could lead to product shortages and damage the company's ability to meet demand.
• Competition and Market Adoption [medium — market]: The market for Prader-Willi syndrome treatments may evolve with new entrants or alternative therapies. Sustaining market share will depend on VYKAT XR's efficacy, safety profile, and competitive pricing against existing or emerging treatments.
• Use of Proceeds from Public Offering [medium — financial]: The substantial cash raised from the July 2025 public offering ($215.721M) needs to be strategically deployed for continued commercialization, potential pipeline development, and operational expenses. Ineffective allocation could hinder long-term growth.

Industry Context

Soleno Therapeutics operates in the rare disease pharmaceutical sector, specifically focusing on treatments for Prader-Willi syndrome. This niche market often presents opportunities for specialized therapies due to unmet medical needs. The competitive landscape is characterized by a limited number of players, but the success of a new therapy like VYKAT XR can significantly alter market dynamics.

Regulatory Implications

The FDA approval of VYKAT XR is a major de-risking event. However, Soleno must continue to adhere to stringent post-market surveillance and manufacturing quality standards. Any adverse findings or changes in regulatory guidance could impact the long-term viability and market access of their product.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-03-26: FDA Approval of VYKAT XR — Marked the critical milestone enabling commercialization and revenue generation for the company's lead product candidate.
• 2025-07-01: Public Offering Completion — Generated $215.721M in net proceeds, significantly bolstering liquidity and financial flexibility.
• 2025-09-30: End of Q3 2025 — Reported significant net income of $26.013M and $66.018M in product revenue, demonstrating a strong financial turnaround.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (A decrease in the accumulated deficit, as seen from $500.741M to $474.728M, indicates the company is becoming profitable and reducing its historical losses.)

Product revenue, net

Revenue generated from the sale of the company's pharmaceutical products after deducting returns, allowances, and discounts. (This is a key indicator of the commercial success of VYKAT XR, showing the company's ability to generate sales post-approval.)

Operating expenses

Costs incurred by a company in its normal business operations, excluding cost of goods sold. (A significant decrease in operating expenses, particularly R&D, post-approval is expected and contributes to improved profitability.)

Research and development (R&D) expenses

Costs associated with the discovery, development, and testing of new products or processes. (A substantial reduction in R&D expenses from $30.138M in Q3 2024 to $8.405M in Q3 2025 reflects the transition from development to commercialization phase.)

Cash and cash equivalents

The most liquid assets held by a company, including currency on hand, bank deposits, and short-term, highly liquid investments. (A significant increase in cash and cash equivalents to $246.662M provides ample resources for operations, further development, and strategic initiatives.)

Contingent liability for Essentialis purchase price

A potential obligation that depends on the outcome of a future event, specifically related to the purchase price of a past acquisition (Essentialis). (This represents a potential future payment, and its balance of $19.473M should be monitored for changes.)

Year-Over-Year Comparison

Soleno Therapeutics has undergone a dramatic financial transformation compared to the prior year. Revenue has shifted from zero to $66.018 million in the third quarter of 2025, driven by the launch of VYKAT XR. This revenue surge has led to a net income of $26.013 million, a stark contrast to the $76.616 million net loss in the same period of 2024. Operating expenses have decreased significantly, primarily due to reduced R&D spending post-approval, contributing to improved profitability. Cash reserves have also substantially increased due to a successful public offering, enhancing the company's financial stability.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by

Filing Documents

• slno-20250930.htm (10-Q) — 3063KB
• slno-ex31_1.htm (EX-31.1) — 14KB
• slno-ex31_2.htm (EX-31.2) — 13KB
• slno-ex32_1.htm (EX-32.1) — 8KB
• slno-ex32_2.htm (EX-32.2) — 8KB
• 0001193125-25-264941.txt ( ) — 11843KB
• slno-20250930.xsd (EX-101.SCH) — 1432KB
• slno-20250930_htm.xml (XML) — 2423KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (unaudited) 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity (unaudited) 5 Condensed Consolidated Statements of Cash Flows (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 28

Controls and Procedures

Item 4. Controls and Procedures 28

—OTHER INFORMATION

PART II—OTHER INFORMATION 31

Legal Proceedings

Item 1. Legal Proceedings 31

Risk Factors

Item 1A. Risk Factors 31

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 63

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 63

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 63

Other Information

Item 5. Other Information 63

Exhibits

Item 6. Exhibits 64 EXHIBIT INDEX 65

SIGNATURES

SIGNATURES 65

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financial Statements

Item 1. Financial Statements Soleno Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2025 December 31, 2024 Assets (unaudited) Current assets Cash and cash equivalents $ 246,662 $ 87,928 Marketable securities 252,272 203,509 Accounts receivable, net 25,506 - Inventory, net 6,674 - Prepaid expenses and other current assets 3,739 2,452 Total current assets 534,853 293,889 Long-term assets Property and equipment, net 150 186 Operating lease right-of-use assets 2,314 2,798 Intangible assets, net 5,347 6,805 Long-term marketable securities 57,148 27,211 Other long-term assets 83 83 Total assets $ 599,895 $ 330,972 Liabilities and stockholders' equity Current liabilities Accounts payable $ 8,145 $ 8,882 Accrued compensation 7,248 4,776 Operating lease liabilities 697 526 Other current liabilities 17,163 4,563 Total current liabilities 33,253 18,747 Long-term liabilities Contingent liability for Essentialis purchase price 19,473 14,791 Long-term debt, net 49,854 49,828 Long-term lease liabilities 2,112 2,472 Other long-term liabilities 398 21 Total liabilities 105,090 85,859 Commitments and contingencies (Note 6) Stockholders' equity Preferred stock, $ 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding - - Common stock, $ 0.001 par value, 100,000,000 shares authorized, 53,703,675 and 45,703,811 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 54 46 Additional paid-in-capital 969,119 696,966 Accumulated other comprehensive income 360 361 Accumulated deficit ( 474,728 ) ( 452,260 ) Total stockholders' equity 494,805 245,113 Total liabilities and stockholders' equity $ 599,895 $ 330,972 See accompanying notes to condense